G1 to S phase transition protein (GSPT1), a small GTPase previously “undruggable target” involved in translation termination, has emerged as a potential therapeutic target for the treatment of cancer with the rapid breakthrough of targeted protein degradation (TPD) technology. The gene discussed is GSPT1; the disease is cancer.